Dupilumab injection in the treatment of moderate to severe atopic dermatitis in adults:a cost-effectiveness analysis
Objective To evaluate the economics of duplizumab in combination with optimal supportive care versus optimal supportive care for moderate-to-severe atopic dermatitis in adults from the perspective of our health system.Methods A Markov model embedded in a decision tree was constructed to compare the long-term cost-utility of dupilumab combined with optimal supportive care versus optimal supportive care,and a sensitivity analysis was performed on the results.Results The results of the basic analysis showed that compared with the optimal supportive care,dupliyuzumab in combination with optimal supportive care resulted in 3.82 more QALYs,while its cost was 125549.42 yuan more.The ICER was 32 854.83 yuan/QALY,which was less than one times China's per capita GDP in 2022,and was economical.Univariate sensitivity analysis showed that factors such as Dupilumab-16-week post-no response utility value,Dupilumab-52-week post response rate and Dupilumab-52-week adherence had a greater impact on the cost changes.The results of the probabilistic sensitivity analysis showed a stable model structure and good robustness.Conclusion In adult patients with moderate-to-severe atopic dermatitis,dupliyuzumab in combination with an optimal supportive care regimen is more cost-effective compared to an optimal supportive care regimen.
万方数据
维普
